South Africa’s Competition Commission has drawn a line under its investigation into Johnson & Jonhson and its Janssen subsidiary over their Sirturo (bedaquiline) tuberculosis treatment, following uproar that the firms were unfairly restricting generic competition in a vital and underserved market.
“Extensive engagements” with the companies have produced several favourite outcomes, including the originator’s announcement in September last year that it...





